EQL Pharma AB (OSTO:EQL) Cyclically Adjusted Revenue per Share: kr7.94 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:EQL EQL Pharma AB OSTO:EQL
42 GF Score
Price kr22.95
! 4 Warning Signs
View Full Analysis

What is EQL Pharma AB Cyclically Adjusted Revenue per Share?

EQL Pharma AB OSTO:EQL +0.22% 42 Cyclically Adjusted Revenue per Share is kr7.94 as of Mar. 2026. GuruFocus rates OSTO:EQL with a GF Score™ of 42/100. The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

EQL Pharma AB's adjusted revenue per share for the three months ended in Mar. 2026 was kr3.983. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is kr7.94 for the trailing ten years ended in Mar. 2026.

During the past 12 months, EQL Pharma AB's average Cyclically Adjusted Revenue Growth Rate was 20.30% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 20.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of EQL Pharma AB was 20.60% per year. The lowest was 20.60% per year. And the median was 20.60% per year.

As of today (2026-07-15), EQL Pharma AB's current stock price is kr22.95. EQL Pharma AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was kr7.94. EQL Pharma AB's Cyclically Adjusted PS Ratio of today is 2.89.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of EQL Pharma AB was 14.06. The lowest was 2.94. And the median was 10.02.


EQL Pharma AB  (OSTO:EQL) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

EQL Pharma AB's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=22.95/7.94
=2.89

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of EQL Pharma AB was 14.06. The lowest was 2.94. And the median was 10.02.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


EQL Pharma AB Cyclically Adjusted Revenue per Share Related Terms


EQL Pharma AB Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for EQL Pharma AB's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

EQL Pharma AB Cyclically Adjusted Revenue per Share Chart

EQL Pharma AB Annual Data
Trend Dec16 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 4.53 5.44 6.60 7.94

EQL Pharma AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.60 6.96 7.20 7.56 7.94

OSTO:EQL vs ZTS, UTHR: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, EQL Pharma AB's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


EQL Pharma AB Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, EQL Pharma AB's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where EQL Pharma AB's Cyclically Adjusted PS Ratio falls into.


OSTO:EQL
42GF Score
EQL Pharma AB OSTO:EQL
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

EQL Pharma AB Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, EQL Pharma AB's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=3.983/133.5600*133.5600
=3.983

Current CPI (Mar. 2026) = 133.5600.

EQL Pharma AB Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201603 0.532 100.751 0.705
201606 0.181 101.019 0.239
201609 0.121 101.138 0.160
201612 0.297 102.022 0.389
201703 0.200 102.022 0.262
201706 0.358 102.752 0.465
201709 0.318 103.279 0.411
201803 0.000 103.962 0.000
201806 0.401 104.875 0.511
201809 0.540 105.679 0.682
201812 0.377 105.912 0.475
201903 0.496 105.886 0.626
201906 0.497 106.742 0.622
201909 0.673 107.214 0.838
201912 0.713 107.766 0.884
202003 0.646 106.563 0.810
202006 3.424 107.498 4.254
202009 0.833 107.635 1.034
202012 0.956 108.296 1.179
202103 0.888 108.360 1.095
202106 1.283 108.928 1.573
202109 1.808 110.338 2.189
202112 4.035 112.486 4.791
202203 6.543 114.825 7.611
202206 1.560 118.384 1.760
202209 2.480 122.296 2.708
202212 2.685 126.365 2.838
202303 2.036 127.042 2.140
202306 1.897 129.407 1.958
202309 2.001 130.224 2.052
202312 2.356 131.912 2.385
202403 2.622 132.205 2.649
202406 2.849 132.716 2.867
202409 2.933 132.304 2.961
202412 3.085 132.987 3.098
202503 3.788 132.825 3.809
202506 3.586 133.699 3.582
202509 2.884 133.480 2.886
202512 3.970 133.390 3.975
202603 3.983 133.560 3.983

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of kr7.94 mean?
EQL Pharma AB (OSTO:EQL) has a Cyclically Adjusted Revenue per Share of kr7.94 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on EQL Pharma AB and its competitors.
Is EQL Pharma AB's Cyclically Adjusted Revenue per Share too high?
EQL Pharma AB's current Cyclically Adjusted Revenue per Share is kr7.94. Overall, EQL Pharma AB has a GF Score™ of 42/100, reflecting its overall financial health beyond just this single metric.
How does EQL Pharma AB's Cyclically Adjusted Revenue per Share compare to ZTS and UTHR?
EQL Pharma AB's Cyclically Adjusted Revenue per Share of kr7.94 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on EQL Pharma AB and its competitors. EQL Pharma AB's current Cyclically Adjusted Revenue per Share is kr7.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EQL Pharma AB stock overvalued right now?
EQL Pharma AB (OSTO:EQL) has a current Cyclically Adjusted Revenue per Share of kr7.94. The current Cyclically Adjusted Revenue per Share is kr7.94. EQL Pharma AB's overall GF Score™ is 42/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For EQL Pharma AB (OSTO:EQL), the current Cyclically Adjusted Revenue per Share is kr7.94 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

EQL Pharma AB Business Description

Other Exchanges 7JK:Germany
Address Stortorget 1, 3rd Floor, Lund, SWE, 222 23
EQL Pharma AB is a pharmaceutical company focused on efficiently and thoughtfully developing and marketing generic drugs. The company operates in one segment, which is medicine. Its niche generics are divided into four parts based on four sales and marketing models: Retail, Hospital, Branded, and Tests. EQL Pharma specializes in identifying, developing, and selling generics, i.e., medicines that are medically equivalent to originator medicines. The company operates in Sweden, Denmark, Norway, Finland, the rest of Europe, and outside Europe, generating the majority of its revenue from Sweden.
42GF Score

Get the complete analysis for OSTO:EQL

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr22.95
Price